Aura Biosciences, Inc. (NASDAQ:AURA) Insider Los Pinos Elisabet De Sells 15,955 Shares

Aura Biosciences, Inc. (NASDAQ:AURA) insider Los Pinos Elisabet De sold 15,955 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total value of $122,374.85. Following the completion of the sale, the insider now directly owns 304,692 shares of the company’s stock, valued at $2,336,987.64. This represents a 4.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Los Pinos Elisabet De also recently made the following trade(s):

• On Tuesday, October 29th, Los Pinos Elisabet De sold 9,200 shares of Aura Biosciences stock. The shares were sold at an average price of $10.74, for a total transaction of $98,808.00.

Aura Biosciences Price Performance

Aura Biosciences stock opened at $7.93 on Thursday. The business has a 50 day simple moving average of $8.50 and a 200 day simple moving average of $8.92. The company has a market capitalization of $396.10 million, a PE ratio of -4.58 and a beta of 0.30. Aura Biosciences, Inc. has a one year low of $6.63 and a one year high of $12.38.

Aura Biosciences (NASDAQ:AURA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.02. Equities analysts anticipate that Aura Biosciences, Inc. will post -1.66 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aura Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Rhumbline Advisers boosted its holdings in shares of Aura Biosciences by 39.6% in the 2nd quarter. Rhumbline Advisers now owns 63,483 shares of the company’s stock worth $480,000 after acquiring an additional 18,011 shares in the last quarter. American Century Companies Inc. acquired a new position in Aura Biosciences in the second quarter worth $119,000. Dimensional Fund Advisors LP grew its holdings in shares of Aura Biosciences by 20.0% during the second quarter. Dimensional Fund Advisors LP now owns 250,375 shares of the company’s stock worth $1,892,000 after purchasing an additional 41,711 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Aura Biosciences by 26.3% in the second quarter. Renaissance Technologies LLC now owns 72,100 shares of the company’s stock valued at $545,000 after buying an additional 15,000 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Aura Biosciences by 14.6% in the second quarter. The Manufacturers Life Insurance Company now owns 64,452 shares of the company’s stock valued at $487,000 after buying an additional 8,194 shares during the last quarter. 96.75% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on AURA shares. Scotiabank upped their price objective on shares of Aura Biosciences from $20.00 to $23.00 and gave the company a “sector outperform” rating in a research report on Friday, October 18th. HC Wainwright reiterated a “buy” rating and issued a $22.00 price objective on shares of Aura Biosciences in a research report on Thursday, November 14th. BTIG Research lifted their price objective on Aura Biosciences from $21.00 to $24.00 and gave the stock a “buy” rating in a report on Friday, October 18th. Finally, Cowen restated a “buy” rating on shares of Aura Biosciences in a research note on Friday, October 18th. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Aura Biosciences currently has an average rating of “Buy” and an average price target of $23.00.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.